Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03)

Murielle Roussel (1) , Benjamin Hebraud (1) , Cyrille Hulin (2) , Xavier Leleu (3) , Thierry Facon (4) , Eileen Boyle (5) , Cyrille Touzeau (6, 7, 8) , Brigitte Pegourie (9) , Aurore Perrot (10) , Anne-Marie Stoppa (11) , Jean-Pierre Marolleau (12) , Philippe Moreau (13, 7, 8) , Herve Avet-Loiseau (14) , Laure Devlamynck , Valerie Lauwers-Cances (15) , Michel Attal (1)

1 IUCT Oncopole - UMR 1037 - Institut Universitaire du Cancer de Toulouse - Oncopole
2 Hôpital Haut-Lévêque [CHU Bordeaux]
3 Hôpital de la Milétrie
4 CIC CHU ( Lille)/inserm
5 NKUA - National and Kapodistrian University of Athens
6 CRCINA-ÉQUIPE 10 - Regulation of Bcl2 and p53 Networks in Multiple Myeloma and Mantle Cell Lymphoma
7 Département d'Hématologie Clinique [CHU Nantes]
8 INCA-DGOS-Inserm - Site de Recherche Intégrée sur le Cancer - SIRIC « ILIAD » [Nantes]
9 Clinique Universitaire d'Hématologie [La Tronche, Grenoble]
10 Service d'Hématologie [CHRU Nancy]
11 Service d’Hématologie [Institut Paoli Calmettes, Marseille]
12 Service clinique des Maladies du Sang
13 CRCINA-ÉQUIPE 11 - Integrative Oncogenomics of Multiple Myeloma Pathogenesis and Progression
14 CRCT - Centre de Recherches en Cancérologie de Toulouse
15 Service d'épidémiologie [Toulouse]

Domaines: Sciences du Vivant [q-bio]

Murielle Roussel, Benjamin Hebraud, Cyrille Hulin, Xavier Leleu, Thierry Facon, et al.. Twice Weekly Induction with Ixazomib-Lenalidomide-Dexamethasone (IRd) Combination Followed By Extended IRD Consolidation and Lenalidomide Maintenance in Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM): A Phase 2 Study from the Intergroupe Francophone Du Myelome (IFM 2014-03). Blood, 2019, 134 (1), ⟨10.1182/blood-2019-123184⟩. ⟨hal-03605012⟩